Atreca to Present at Upcoming Virtual Investor Conferences
09 11월 2021 - 6:30AM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that it will present at the following upcoming virtual investor
conferences:
Cowen’s 5th Annual IO Next SummitMonday,
November 15th, 2021Fireside chat time: 10:15 a.m. EST
Stifel Nicolaus Healthcare Conference 1 Monday,
November 15th, 2021Fireside chat time: 3:20 p.m. EST
Evercore ISI 4th Annual HealthCONx
ConferenceTuesday, November 30th, 2021Fireside chat time:
10:55 a.m. EST
Live audio webcasts of the presentations can be accessed through
the Events & Presentations section of the Company's website at
http://ir.atreca.com. An archived replay will be available on the
Company's website for 90 days following each live presentation.
About Atreca, Inc.Atreca is a biopharmaceutical
company developing novel antibody-based immunotherapeutics
generated by its differentiated discovery platform. Atreca's
platform allows access to an unexplored landscape in oncology
through the identification of unique antibody-target pairs
generated by the human immune system during an active immune
response against tumors. These antibodies provide the basis for
first-in-class therapeutic candidates, such as our lead product
candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in
multiple solid tumor cancers is currently enrolling patients. For
more information on Atreca, please visit www.atreca.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions. These statements include those related to our strategy
and future plans, including statements regarding the development of
ATRC-101 and our preclinical, clinical and regulatory plans and the
timing thereof. Our actual results may differ materially from those
indicated in these forward-looking statements due to risks and
uncertainties related to the initiation, timing, progress and
results of our research and development programs, preclinical
studies, clinical trials, regulatory submissions, and other matters
that are described in our filings with the Securities and Exchange
Commission (SEC) and available on the SEC’s website at www.sec.gov,
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of our most recently filed annual report on Form 10-K and quarterly
report on Form 10-Q. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial Officerinfo@atreca.com
Investors:Alex Gray, 650-779-9251agray@atreca.com
Media:Rachel Ford Hutman,
301-801-5540Rachel@fordhutmanmedia.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024